Report overview
Viral conjunctivitis therapeutics is undergoing a transitional phase. Currently, there is no drug available for the treatment of viral conjunctivitis. However, the presence of a robust pipeline indicates towards a thriving future. The global market for viral conjunctivitis pipeline drugs is likely to exhibit a thumping CAGR of 69.60% between 2020 and 2023 and reach an opportunity worth US$462.4 mn by the end of the forecast period.
This report contains market size and forecasts of Viral Conjunctivitis Drugs in Global, including the following market information:
Global Viral Conjunctivitis Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Viral Conjunctivitis Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
FST-100 Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Viral Conjunctivitis Drugs include Adenovir Pharma, Allergan, NanoViricides, Takeda, NovaBay Pharmaceuticals, Novartis, Panoptes Pharma and NicOx, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Viral Conjunctivitis Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Viral Conjunctivitis Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Viral Conjunctivitis Drugs Market Segment Percentages, by Type, 2021 (%)
FST-100
APD-209
Global Viral Conjunctivitis Drugs Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Viral Conjunctivitis Drugs Market Segment Percentages, by Application, 2021 (%)
Hospitals
ASCs
Others
Global Viral Conjunctivitis Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Viral Conjunctivitis Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Viral Conjunctivitis Drugs revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Viral Conjunctivitis Drugs revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Adenovir Pharma
Allergan
NanoViricides
Takeda
NovaBay Pharmaceuticals
Novartis
Panoptes Pharma
NicOx
